<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363290">
  <stage>Registered</stage>
  <submitdate>6/03/2013</submitdate>
  <approvaldate>8/03/2013</approvaldate>
  <actrnumber>ACTRN12613000279729</actrnumber>
  <trial_identification>
    <studytitle>TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma</studytitle>
    <scientifictitle>TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym>HPV Oropharynx</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Radiation Treatment: 70 Gy in 35 fractions, 5 days a week over 7 weeks. 
Systemic Treatment: Weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)</interventions>
    <comparator>Radiation Treatment: 70 Gy in 35 fractions, 5 days a week over 7 weeks. 
Systemic Treatment: Weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the area under curve of symptom severity between weekly cisplatin and RT versus weekly cetuximab and RT from baseline to week 20 (13 weeks post-completion of radiotherapy) as measured by M.D. Anderson Symptom Inventory - Head and Neck Module (MDASI-HN). </outcome>
      <timepoint>MDASI-HN; baseline, treatment weeks 1-7, 1, 3, 5, 9 and 13 weeks post treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare other MDASI-HN endpoints: Symptom Interference Score, Modified MDASI-HN Symptom Score, MDASI-HN Symptom Clusters and individual item scores at individual time points. </outcome>
      <timepoint>baseline, treatment weeks 1-7, post radiation weeks 1, 3, 5, 9 and 13 as well as 6mths, 12mths and 24mths post treatment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare health-related quality of life as measured by Functional Assessment of Cancer Therapy  Head and Neck (FACT-HN)</outcome>
      <timepoint>Baseline, post RT 9wks, 6mths, 12mths, 24mths and 36mths. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare speech and dietary function as measured by the Performance Status Scale for Head &amp; Neck Cancer Patients (PSS-HN)</outcome>
      <timepoint>baseline, post RT 13wks, 6mths, 12mths, 24mths and 36mths. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare clinician-assessed acute and late toxicity using toxicity grading (CTCAE v4.0) reported as worst toxicity and as overall acute toxicity burden (T-score).  </outcome>
      <timepoint>Each visit (baseline to 60 months post radiation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare unacceptable locoregional treatment outcome (ULTO) defined as either locoregional failure or specific severe late treatment-related locoregional toxicities.   </outcome>
      <timepoint>Clinical Examinations; each visit baseline to 60 months post treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare rate of enteral feeding at 12months from end of RT. </outcome>
      <timepoint>12mnths post RT. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare functional swallowing outcome measured by swallowing video fluoroscopy.</outcome>
      <timepoint>Baseline, 12mths and 24mths post RT.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare hearing impairment as measured by audiometry</outcome>
      <timepoint>baseline and 12months post RT.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare hearing impact on health related quality of life (HRQOL) as measured by total score of Hearing Handicap Inventory for Adult Screenign version (HHIA-S) </outcome>
      <timepoint>baseline, treatment wk7 and post RT 1 wk, 13 wks, 6mths, 12mths and 24mths. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare depression and anxiety, as measured by depression and anxiety scales of HADS. </outcome>
      <timepoint>Baseline, treatment wk 7 and post RT 1wk, 5wks, 13wks, 6mths, 12mths and 24mths. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare overall survival, defined as time from randomisation to death.</outcome>
      <timepoint>Clinical Examinations; each visit baseline to 60 months post treatment 
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare failure-free survival, defined as time from randomisation to failure (locoregional or distant) or death. </outcome>
      <timepoint>Clinical Examinations; each visit baseline to 60 months post treatment. 

Radiological examinations; baseline and post RT 13 wks, 6 mths, 12 mths, 24 mths, 36mths and any time of clinically indicated.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare time to locoregional failure defined as time from randomisation to locoregional failure. </outcome>
      <timepoint>Clinical Examinations; each visit baseline to 60 months post treatment. 

Radiological examinations; baseline and post RT 13 wks, 6 mths, 12 mths, 24 mths, 36mths and any time of clinically indicated.
 
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare FDG-PET or FDG-PET-CT complete response rate at 13 weeks post RT. </outcome>
      <timepoint>Baseline and 13 weeks post-completion Raditaiton therapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the pattern of disease failure (locoregional [recurrence at primary tumour site and/or regional nodes], distant, both). </outcome>
      <timepoint>Radiological examinations; baseline and post RT 13 wks, 6mths, 12mths, 24mths, 36mths and any time of clinically indicated.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare quality adjusted life years (QALYS) using the EQ-5D-5L. </outcome>
      <timepoint>Baseline and post treatment (13 weeks, 6 months, 12 months, 24months and 36 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare work status and time to return to work questionnaire</outcome>
      <timepoint>Baseline, treatment wk7 and post RT 1wk, 13wks, 6mths, 12mths, 24mths and 36mnths.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare cost of health resource utilisation by 
comparing the cost of administrating each arm in addtion to the treatment of toxcicites (e.g. need for feed tube insertion, hopsitalisations, salvage surgery, supportive care medicines)</outcome>
      <timepoint>End of Study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Aged 18 years or older
2. Has provided written Informed Consent for participation in this trial 
3. Histologically confirmed squamous cell carcinoma of the oropharynx with p16 positive status confirmed locally by immunohistochemistry 
4. Stage III (excluding T1-2N1) or stage IV (excluding T4, N3, and distant metastasis) if smoking history of &lt; /=10 pack years. If &gt; 10 pack years nodal disease must be N0  N2a. 
5. If an excisional biopsy has been performed, patients remain eligible for the study provided there is clinically measurable disease prior to commencing RT. The residual disease should still meet the stage criteria required for the trial e.g. excisional biopsy of a node with residual T3 primary, or tonsillectomy for T1 primary with residual &gt; N2a nodes.
6. No prior treatment for oropharyngeal cancer
7. Adequate haematological, renal, and hepatic function as defined by, 
a)  Absolute neutrophil count (ANC, segs + bands) &gt; /= 1.5 x 109/L
b) Platelet count &gt; /= 100 x 109/L
c) Total bilirubin &lt; /= 1.5 x upper normal limit 
d) ALT  &lt; /= 2.5 x upper normal limit 
e) Calculated creatinine clearance (Cockcroft-Gault formula) or isotopic GFR &gt; 55ml/min 
8. ECOG performance status score of 0-1 
9. Participants capable of childbearing are using adequate contraception and intend to continue use of contraception for at least 6 months following completion of treatment
10. Negative pregnancy test within 72 hours prior to randomisation of women who are of childbearing potential
11. Suitable for follow-up for at least 24 months as per trial protocol.
12. Sufficient proficiency in English, cognitive capacity and willingness to complete questionnaires</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. History of unknown primary of the head and neck
2. T4, N3 or distant metastases
3. Smoking history &gt;10 pack years with N2b or c nodal status
4. Women who are pregnant or lactating.
5. Previous radiotherapy to the area to be treated (excluding superficial radiotherapy for a cutaneous malignancy)
6. Previous cisplatin or carboplatin chemotherapy
7. Prior EGFR targeted therapy of any kind
8. Primary surgery to the affected area (excisional biopsy allowed)
9. Peripheral neuropathy &gt; /= grade 2 (CTCAE v4.0)
10. Sensori-neural hearing impairment &gt;= grade 2 (CTCAE v4.0, hearing impaired, not enrolled on a monitoring program) which may be exacerbated by cisplatin (Audiometric abnormalities without corresponding clinical deafness will not be grounds for exclusion) 
11. Tinnitus &gt; /= grade 2 (CTCAE v4.0)
12. History of interstitial lung disease or evidence of interstitial lung disease on pre-registration CT
13. History of myocardial infarction within 12 months prior to study entry, uncontrolled congestive heart failure, unstable angina, active cardiomyopathy, unstable arrhythmia, uncontrolled psychotic disorders, active serious infections, active peptic ulcer disease, immunosuppression due to post-organ transplantation or use of immunosuppressants for autoimmune disorders
14. Patients known to be HIV positive
15. Other cancer that was diagnosed:
a) more than 5 years prior to current diagnosis with (i) subsequent evidence of disease recurrence or (ii) clinical expectation of recurrence is greater than 10% or
b) within 5 years of the current diagnosis, with the exception of successfully treated basal cell or squamous cell skin carcinoma, in situ melanoma, or carcinoma in situ of the cervix</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2013</anticipatedstartdate>
    <actualstartdate>17/06/2013</actualstartdate>
    <anticipatedenddate>31/05/2021</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <currentsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2025</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,WA,VIC</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Peter MacCallum Cancer Institute - East Melbourne</hospital>
    <hospital>The Canberra Hospital - Garran</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Riverina Cancer Care Centre - Wagga Wagga</hospital>
    <hospital>The Chris Oâ€™Brien Lifehouse - Camperdown</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>The Townsville Hospital - Douglas</hospital>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Gold Coast Hospital - Southport</hospital>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group</primarysponsorname>
    <primarysponsoraddress>TROG Central Office
PO Box 88
Waratah NSW 2298</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra 
ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck Serono Australia </fundingname>
      <fundingaddress>Units 3-4, 25 Frenchs Forest Road East, Frenchs Forest, NSW, 2086</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to compare radiation treatment combined with either cetuximab or cisplatin in patients with locoregionally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC) (located at the base of tongue or tonsil)

Who is it for?
You may be eligible to join this study if you are aged 18 years or more, and have been diagnosed with locoregionally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC). You should not have received any prior treatment for this cancer.

Trial details;
Participants in this trial will be randomly (by chance) allocated to one of two groups. Participants in one group will receive radiation treatment 5 days a week over 7 weeks, in conjunction with weekly doses of a drug called cetuximab. This drug is administered intravenously, i.e. directly into the vein. 

Participants in the other group will receive radiation treatment 5 days a week over 7 weeks in combination with the chemotherapy drug cisplatin, which is also administered intravenously.

Participants will be assessed weekly during treatment, then at 1, 3, 5, 9, 13 weeks post-treatment and at months 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 42, 48, 54, and 60 post-completion of treatment. Assessments will involve blood tests, questionnaires, clinical examination, hearing tests, swallowing tests, and radiological examination. The main research question being answered is whether those treated with weekly cetuximab and conventionally fractionated radiotherapy will experience less acute symptom severity than patients receiving weekly cisplatin and conventionally fractionated radiotherapy.
</summary>
    <trialwebsite>www.trog.com.au</trialwebsite>
    <publication>nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre Ethics Committee</ethicname>
      <ethicaddress>Peter MacCallum Cancer Centre Ethics Committee Peter MacCullum Cancer Centre Locked Bag 1 A'Beckett Street MELBOURNE VIC 8006
</ethicaddress>
      <ethicapprovaldate>28/03/2013</ethicapprovaldate>
      <hrec>HREC/13/PMCC/6</hrec>
      <ethicsubmitdate>8/02/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Anetta Matera</name>
      <address>Peter MacCallum Cancer Centre
Locked Bag No 1, 
ABeckett St, 
Melbourne, VIC 8006, Australia.</address>
      <phone>+61 3 9656 3661</phone>
      <fax />
      <email>Anetta.Matera@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Anetta Matera</name>
      <address>Peter MacCallum Cancer Centre
Locked Bag No 1, 
ABeckett St, 
Melbourne, VIC 8006, Australia.</address>
      <phone>+61 3 9656 3661</phone>
      <fax />
      <email>Anetta.Matera@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>TROG Central Office
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 40143910</phone>
      <fax />
      <email>administration@trog.com.au </email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Danny Rischin</name>
      <address>Peter MacCallum Cancer Centre
Locked Bag No 1, 
ABeckett St, 
Melbourne, VIC 8006, Australia.</address>
      <phone>+61 3 9656 1408</phone>
      <fax />
      <email>danny.rischin@petermac.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>